CHELMSFORD, MA — ZOLL Medical Corporation (NASDAQ: ZOLL), a manufacturer of resuscitation devices and related software solutions, today announced that it received clearance from the U.S. Food and Drug Administration (FDA) to market and sell the ZOLL E Series® with Real CPR Help™ technology. ZOLL’s Real CPR Help allows rescuers to instantly see and hear how well they are performing the rate and depth of CPR chest compressions. With this clearance, the E Series becomes ZOLL’s first advanced pre-hospital device to provide this instantaneous feedback.

“Typical professional defibrillators on the market today only provide generic, ancillary support to rescuers when it comes to CPR performance,” said Richard A. Packer, President and Chief Executive Officer of ZOLL. “These devices merely tell rescuers to start CPR at the appropriate moment during a resuscitation attempt. ZOLL’s Real CPR Help technology can provide rescuers with assistance beyond merely prompting them to start CPR, so they are better equipped to improve their CPR performance and help cardiac arrest patients when it matters most.”

Mr. Packer continued, “Improving CPR quality is a key to increasing survival rates from cardiac arrest. Given where the science of resuscitation is headed, we believe that this type of instantaneous feedback will be standard care in the next five years. To that end, we envision a day when our entire line of AEDs and professional defibrillators will provide ZOLL’s Real CPR Help technology, including our flagship M Series and M Series CCT devices.”

All cardiac arrest victims need immediate and effective CPR. Furthermore, less than half of these victims require defibrillation initially since they are experiencing heart rhythms that are not “shockable;” that is, defibrillation will not help these victims’ hearts beat normally again. The critical action is CPR, which achieves minimal but effective blood flow to feed oxygen to the heart and brain. CPR is also associated with a return of a “shockable” heart rhythm, making defibrillation possible later in the resuscitation event.

Sudden cardiac arrest (SCA) is an abrupt disruption of the heart’s function, which causes a lack of blood flow to vital organs. This lack of blood flow can result in the loss of blood pressure, pulse, and consciousness. SCA is the leading cause of unexpected death in the world and strikes without warning. In the U.S. alone, there are more than 460,000 deaths each year from out-of-hospital cardiac arrest. Currently, only about 6 percent of victims survive.

About ZOLL Medical Corporation
ZOLL Medical Corporation is committed to developing technologies that help advance the practice of resuscitation. With products for pacing, defibrillation, circulation (with ZOLL’s See-Thru CPR™ and Real CPR Help™ technologies), ventilation, and fluid resuscitation, ZOLL provides a comprehensive set of technologies that help clinicians, EMS professionals, and lay rescuers resuscitate sudden cardiac arrest or trauma victims. ZOLL also designs and markets software that automates the documentation and management of both clinical and non-clinical information.

ZOLL markets and sells its products in more than 140 countries. The Company has direct operations, distributor networks, and business partners throughout the U.S., Canada, Latin America, Europe, the Middle East and Africa, Asia, and Australia.

Certain statements contained in this press release regarding matters that are not historical facts are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, ZOLL’s ability to compete in the resuscitation business; acceptance of its recently launched products; changes in regulations affecting the healthcare industry; global economic conditions; and those other factors discussed in the section entitled “Risk Factors” in ZOLL’s Annual Report on Form 10-K, which was filed with the SEC on December 15, 2006.